Tumor cell heterogeneity is a fundamental characteristic of cancer that has profound implications for cancer therapy (1-3). Melanoma, a tumor arising from pigmented cells, is particularly accessible for the study of tumor heterogeneity . Metastatic melanoma cells can vary widely in their degree of pigmentation, cell morphology, and growth rate (4, 5), and these differences can be observed in different metastases and even among the various cells within individual lesions of patients with melanoma . There are a number of biological factors that could regulate the phenotypic heterogeneity observed in melanoma cells. One possibility is that melanoma heterogeneity reflects a corresponding diversity in the phenotype of normal cells undergoing melanocyte differentiation. According to this view, patterns of gene expression change as cells progress through distinct cyte lineage. To pursue this idea, we analyzed the anti phenotype of melanocytes and melanoma (6). Antigens could be grouped into four categories: (a) not present on melanocytes, (b) expressed by fetal and newborn melanocytes but not adult, (c) expressed by adult but not fetal/newborn melanocytes, and (d) equally expressed on fetal, newborn, and adult melanocytes.
lations that have allowed the analysis of the coordinate expression of phenotypic standard (Sigma Chemical Co .) . Tyrosinase activity was determined by the method of Pomerantz (20) , modified as previously described (21) . Measurements of tyrosinase were performed in triplicate from cells extracted in PBS, 0 .5% Nonidet-P40 (NP-40), 50 AM tyrosine, 50 PM DOPA and 5 ACi/ml 3',5'-['H]tyrosine (New England Nuclear, Boston, MA) . Tyrosinase activity was expressed as the ratio of 'H20 formed by (10 6 test cells)/(106 tyrosinase-negative renal cancer cell line SK-RC-6) . Ratios of g H 2 0 calculated per milligram of protein of cell extracts gave results within 20% of ratios calculated from cell number .
Radioimmunoprecipitation . Analysis of immunoprecipitates was performed as previously described (22) . Cultured cells were labeled with [s H]glucosamine (New England Nuclear) for 72 h . 0 .5% NP-40 cell lysates were prepared and equivalent sH counts per minute (determined by precipitation at 4°C with 10% vol/vol TCA) of lysate were used for immunoprecipitation with each antibody. Immunoprecipitation was carried out with monoclonal antibody plus rabbit anti-mouse Ig and PA-Sepharose (Pharmacia Inc .) and was analyzed on 9% SDS-PAGE .
Results

Serological Typing ofMelanomas: Characterization of Antigenic Phenotypes and Selection of Cell Linesfor Subcloning
28 melanoma cell lines from 26 patients were evaluated for antigen expression, tyrosinase activity, cell morphology, and pigmentation ( Fig . 1 ) . 11 antigen systems were analyzed in the present study because they define subsets of melanomas, have distinct patterns of expression on fetal, newborn, and adult melanocytes, and have been interpreted to map to different stages of melanocyte differentiation (early, intermediate, or late) . Antigens A010, epidermal growth factor receptor (EGFR), melanoma chondroitin sulfate proteoglycan (mCSP), and la are early markers of melanocyte differentiation, antigens M111 and common acute lymphoblastic leukemia (antigen) (CALLA) are markers of an intermediate stage, and antigens C350, CF21, TA99, Mel 1, and M144 are late markers (Table 1) (6, 23) .
Two melanoma cell lines (highlighted in Fig . 1 ) were selected for more detailed studies : (a) SK-MEL-131, derived from patient FD, has an epithelioid morphol-FIGURE 1 . Serologic typing of melanoma cell lines for melanocyte differentiation markers. Antigen expression is graded by titers : +, 1/200 to 1/1,000; ++, >1/1,000 to 1/10,000 ; +++, >I/10,000 to 1/100,000; ++++, >1/100,000 . Morphology (MORPH.): E, epithelioid; S, spindle; D, dendritic. Pigmentation is determined as outlined in Materials and Methods. Tyrosinase activity is expressed as the ratio of melanoma/control renal cancer culture (SK-RC-6).
ogy, lacks pigmentation, and expresses early melanocyte markers, and (b) SK-MEL-23 from patient AP contains a mixture of spindle and polydendritic cells, is deeply pigmented, expresses high tyrosinase activity and late markers, and is representative of cells at a late stage of melanocyte differentiation.
Heterogeneity in Tumors from Patients FD and AP
There is a high degree of variability in cell morphology, pigmentation, and expression of melanocyte differentiation antigens in tissue sections of metastatic melanoma lesions (4, 12, 14, 24) . Characteristically, individual differentiation antigens are detected on only a proportion of cells within tumor specimens. For example, we have found that la, mCSP, M 111, CF21, TA99, and C350 antigens are expressed on distinct subsets of melanoma cells in reactive tumors (12, 14) . To investigate this phenotypic heterogeneity of melanoma, we examined the phenotype of cells in the original tumor lesions of patients FD and AP. The cell line SK-MEL-131 was established from an axillary lesion resected from patient FD and the cell line SK-MEL-23 was derived from a surgically resected metastatic tumor in the axilla of patient AP. Tissue sections from paraffin-embedded blocks of these lesions were examined for cell morphology, pigmentation, and antigen expression . Substantial variability in cell shape and pigmentation was observed . Each lesion contained a mixture of epithelioid and spindle cells ( Fig. 2A) areas of pigmented and nonpigmented tumor (Fig. 2B ). We were unable to measure antigen expression, inasmuch as none of the determinants of differentiation antigens that we tested were stable after paraffinization-deparaffinization. 19) , and >120 h (clone 711) . These results show that some melanoma clones corresponding to late stages of differentiation grow at a very slow rate, but the rate of growth of clones at other stages was similar. All subclones of SK-MEL-131 and SK-MEL-23 have been maintained for more than 2 yr in culture and phenotypes have remained stable over this period unless tissue culture conditions were manipulated (e.g., deprivation of serum, very high cell densities) . Each clone responded ;uadistinct manner tninducing agents . Clone 3 .44 was induced to differentiate by PMA and clones 22 .a and 22 by cholera toxin, whereas clone 1 .36-1-5 was induced to undergo only minor changes in phenotype by either PMA or cholera toxin. Thus, each clone could be induced to undergo o shift in differentiation characteristics ( varied-only minimal changes were detected after induc 1 .36-1-5 by the combination of PMA and cholera toxin, but a major s differentiation state of clone 22 .a from intermedi observed during exposure to cholera toxin. Major alterations in not clearly evident until after 2-3 wk. For example, during 22.a, there was a gradual increase of pigment, appearance of C350 an between days 4 and 7, and appearance of antigens CF21 and TA99 between the (Fig. 6 ). These changes in antigen expression were accompanied by the occasional appearance of dendritic cells, but the cells remained nonpigmented and tyrosinase-negative (Fig. 7A) . Once clone 1 .36-1-5 was induced with PMA and cholera toxin, the induced antigenic changes were maintained when PMA and cholera toxin were removed from the culture medium . No phenotypic changes were observed when clone 1 .36-1-5 was exposed to either PMA or cholera toxin alone. PMA induced long dendritic processes on the spindle-shaped clone 3.44 and augmented tyrosinase activity and melanin synthesis (Fig. 7 B) . These changes were accompanied by a change in antigen profile, with downregulation of the early markers mCSP and la and induction of the late markers C350 and CF21 (Fig. 6 ). After induction with PMA, the altered phenotype was maintained in the absence of PMA . Similar but less pronounced changes were observed in the presence of PMA and cholera toxin, and cholera toxin alone had no effect on the phenotype of clone 3 .44. with PMA, and clone 22 .a with cholera toxin as described in the text. Expression of antigens AO 10, CSP, la, CALLA, M111, and C350 were tested by anti-mouse Ig assays : antibody dilutions were 1/1,000, 1/10,000, 1/100,000, and 1/1,000,000 . Expression of CF21 and TA99 were tested by indirect immunofluorescence assays: antibody dilutions were 1/100, 1/1,000, 1/10,000, and 1/100,000. markers (mCSP, la, and M111) were downregulated while late markers (C350, CF21, and TA99) were induced (Fig. 6 ). These serologic results were confirmed by radioimmunoprecipitation of antigens from induced and control cells (Fig.  9) . The change in differentiation program produced by cholera toxin was stable and was not reversed by removing cholera toxin from the culture medium. PMA alone and the combination of PMA and cholera toxin induced clone 22 .a cells to become more dendritic, but there was no change in other traits .
Phenotypes of Clones from
Clone 22 (late stage). Cholera toxin induced clone 22 to become heavily pigmented and polydendritic (Fig. 8) . A decrease in the expression of the melanosomal antigen TA99 was observed, but no other antigen changed expression (data not shown) . The doubling time of clone 22 increased from 52 to >120 h after 21 d of exposure to cholera toxin. PMA alone and the combination of PMA and cholera toxin produced elongated, spindle-shaped cells but no other alteration, again suggesting that exposure to PMA blocked the differentiating effects of cholera toxin .
Discussion
Cells of the melanocyte lineage undergo phenotypic changes as they migrate from the neural crest to their final destination in the skin (25, 26) . The most striking trait of mature melanocytic cells is the presence of the pigment melanin . The synthesis of melanin is regulated by the specialized cellular enzyme tyrosinase, and the expression of melanin and tyrosinase activity is associated with the expression of a set of cell surface and melanosomal antigens (6, 23, 27) . In earlier studies, we have proposed a model for melanocyte differentiation based on the expression of these traits by a panel of melanoma cell lines and by cultured fetal, newborn, and adult melanocytes (6) . The present investigations with cloned melanoma cell lines have extended these studies and have confirmed that the pattern of antigen expression is related to other differentiation traits, such as pigmentation, tyrosinase activity, and morphology . The induction of coordinated changes in the differentiation program of these clones by PMA and cholera toxin was in accordance with predictions from this model.
There are two major stages of melanocyte differentiation in this model-early and late-with an intermediate stage that characterizes the transition from early to late. Melanoma cells at an early stage appear to be committed to the melanocyte phenotype, because they express markers that characterize the melanocyte lineage (6) and they stably maintain this phenotype unless induced to differentiate. The late stage coincides with the emergence of a specialized phenotype, characterized by the appearance of pigment and associated markers. The transition from the early to the mature phenotype is associated with a coordinated change in the pattern of expression of differentiation traits . Even within a stage of differentiation, there appears to be a hierarchy for expression of traits . For instance, as melanocytic cells mature, late antigens do not appear synchronously but rather are expressed in a specific order-C350, then CF21, followed by TA99.
Each of these differentiation traits can be expressed by melanomas in a heterogeneous fashion. For example, it is not unusual to observe a nonpigmented metastasis next to a pigmented metastasis in a patient with melanoma . Likewise, melanocyte differentiation antigens are characteristically expressed by only a subset of melanoma cells within individual lesions (12, 24) . These observations have led us to consider whether the remarkable phenotypic heterogeneity observed in melanomas is due to the coexistence of populations of cells at different stages of differentiation. It is clear from our experiments that melanomas are not frozen at a specific stage of differentiation. Appropriate signals, such as phorbol esters, activators of cellular cyclic AMP (e.g., cholera toxin, melanocytestimulating hormone) or cyclic AMP analogues can induce melanoma cells to undergo variable degrees of differentiation (27) (28) (29) (30) (31) (32) (33) (34) . In particular, cyclic AMP has been implicated in the regulation of melanin synthesis in vivo and our experiments suggest that cyclic AMP and other pathways may be involved in the coordinated upregulation and downregulation of a family of traits in melanocytic cells. When melanoma clone 22 .a was induced to mature, late markers (melanin synthesis, tyrosinase activity, the melanosomal markers TA99 [gp75] and CF21, and the C350 cell surface glycoprotein [gpl80]) were expressed, while in the same cells early and intermediate markers (Ia antigens, MI I I [gpI 10], CALLA [gpI00], and the melanoma chondroitin sulfate proteogiycan antigens [mCSP]) were simultaneously downregulated. We have noted that melanoma clones vary in their response to cholera toxin or PMA. The response or lack of response by individual clones to induction must be related to biological traits that differ from one clone to another. One explanation is that intracellular pathways mediating the differentiation program change as cells proceed through the melanocyte lineage. Alternatively, heterogeneity in expression of receptors or response to these signals is unrelated to the differentiation program.
The regulation of la (class II major histocompatibility) antigens by melanoma cells is of particular interest. la antigens are not expressed by mature melanocytes (unless induced by gamma interferon [35] ), but they are constitutively expressed by a proportion of melanomas (6, (35) (36) (37) . One explanation for this constitutive expression is that la expression is regulated by events occurring during the process of malignant transformation . In support of this hypothesis, recent experiments have demonstrated the induction of la by the introduction of ras oncogenes into melanocytes (38) . In contrast, serological typing of melanomas has shown that expression of la on individual tumors corresponds to stage of melanocyte differentiation (6) . Our interpretation of this data is that la expression is regulated during melanocyte differentiation, the assumption being that la is expressed by precursor cells in the melanocyte lineage . Induction experiments with cloned melanoma cells confirm that la can be regulated during differentiation of melanoma cells. The fact that tumors can be composed of complex populations of cells should be taken into consideration in the evaluation of agents that induce differentiation. Such agents can be used to induce terminal differentiation of tumor cells (40) or to manipulate the expression of antigens on tumor cells, for instance, to optimize antigen expression on lesions in preparation for targeting with monoclonal antibodies . An agent that induces differentiation of cells at one stage may not have the same biological effect on cells at another stage. In addition, agents may interfere with each other in effective induction of differentiation. For instance, we and others have observed that PMA can block the induction of late differentiation markers in melanoma cells (41) . Cloned cell lines have definite advantages over parental cell strains in the analysis of agents that induce shifts in the differentiation state . In this regard, neither PMA nor cholera toxin alone or in combination was able to induce major changes of phenotype in 10 noncloned, established melanoma cell lines (Houghton, A. N., and F. X. Real, unpublished observation) including SK-MEL-131 and SK-MEL-23. Cloned subpopulations permitted a dissection of the regulation of differentiation traits in distinct subpopulations . Understanding signals involved at each stage of melanocyte differentiation will lead to strategies aimed at the terminal differentiation of melanoma cells in vivo.
Summary
Phenotypic heterogeneity is a characteristic feature of tumor lesions in patients with melanoma . Variability can be observed in cell morphology, pigmentation, and antigen expression . To test whether phenotypic heterogeneity could be the result of events regulated during cell differentiation, we evaluated the expression of a panel of differentiation traits on melanoma cells. Metastatic melanoma lesions from two patients, designated FD and AP, were examined histologically and found to contain mixed populations of cells. Established melanoma cell lines derived from each of these lesions were subcloned at early passage in culture (passages 7 and 8) to create a panel of clones derived from each tumor. There was heterogeneity in the expression of differentiation-related traits in clones, corresponding to distinct phenotypes observed within the original tumors . Clones from patient FD corresponded to early to intermediate stages of melanocyte differentiation, and clones from patient AP ranged from intermediate to late stages . The influence of cholera toxin and PMA. on differentiation of parental cultures and subclones was studied. Results of induction studies demonstrated a number of features of differentiation of melanoma cells: (a) regulation of differentiation traits is coordinated as a program of traits expressed sequentially at specific stages ; (b) early traits, such as the epidermal growth factor receptor and the melanoma chondroitin sulfate proteoglycan antigen, are downregulated as melanoma cells differentiate, whereas late markers, including melanin, tyrosinase activity, and antigens expressed in mature melanosomes, are upregulated; (c) la (class II major histocompatibility) antigens are characteristically expressed on melanomas corresponding to early or intermediate stages of differentiation and are regulated as part of the differentiation program; (d) minimal changes in stage of differentiation were observed during induction of parental cultures with either cholera toxin or PMA, whereas definite shifts in differentiation could be induced in selected cloned subpopulations . We conclude that melanoma cells are not frozen at a specific stage of differentiation, but rather are capable of differentiating when exposed to appropriate signals. Diversity in the differentiation state of melanoma cells can account for much of the phenotypic heterogeneity observed in melanoma lesions .
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